D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 µM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 µM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS (HY-116282C)-induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].
Molecular Weight:
484.45
Purity:
99.77
CAS Number:
[2676188-98-8]
Formula:
C22H28O12
Target:
MyD88,p38 MAPK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
